Thrivent Financial for Lutherans Reduces Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Thrivent Financial for Lutherans cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,158,750 shares of the medical research company’s stock after selling 99,212 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Edwards Lifesciences were worth $85,739,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $30,000. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $46,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research analyst reports. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday, February 12th. Finally, Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Down 0.5 %

Shares of EW stock opened at $70.31 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $41.33 billion, a PE ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock has a fifty day moving average of $71.61 and a two-hundred day moving average of $70.35. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other news, VP Daniel J. Lippis sold 400 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company’s stock, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven R. Loranger sold 5,739 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock worth $3,715,776 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.